Abstract
Iron abnormalities within the brain are associated with several rare but severe neurodegenerative conditions. There is growing evidence that more common systemic iron loading disorders such as hemochromatosis can also have important effects on the brain. To identify features that are common across different forms of hemochromatosis, we used microarray and real-time RT-PCR to assess brain transcriptome profiles of transferrin across all three models, there was perfect (100%) directional concordance (i.e. transcripts were increased in all models or decreased in all models). Comparison of the two models of hereditary hemochromatosis, which showed more pronounced changes than the dietary ironsupplemented mice, revealed numerous common molecular effects. Pathway analyses highlighted changes for genes relating to long-term depression (6.8-fold enrichment, p=5.4x10 -7 ) and, to a lesser extent, long-term potentiation (3.7-fold enrichment, p=0.01), with generalized reductions in transcription of key genes from these pathways, which are involved in modulating synaptic strength and efficacy and are essential for memory and learning. The agreement across the models suggests the findings are robust and strengthens previous evidence that iron loading disorders affect the brain. Perturbations of brain phenomena such as long-term depression and long-term potentiation might partly explain neurologic symptoms reported for some hemochromatosis patients.
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Introduction
Iron has crucial roles in brain functions such as neurotransmitter synthesis and myelination but abnormally high brain iron levels have been proposed to be associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and neurodegeneration with brain iron accumulation (reviewed (Johnstone and Milward, 2010b) ). However debate surrounds the question of whether disorders of systemic iron accumulation, such as hereditary hemochromatosis, can also have detrimental effects on the brain.
Hereditary hemochromatosis is a genetic disorder characterized by iron loading in peripheral tissues such as the liver (Pietrangelo, 2006; Ayonrinde et al., 2008) . Evidence from case studies suggests that some hemochromatosis patients also have abnormal iron accumulation in the brain, particularly in the basal ganglia (Nielsen et al., 1995; Berg et al., 2000; Rutgers et al., 2007) and choroid plexus, pituitary, periventricular and perivascular regions (reviewed (Russo et al., 2004) ). However there have been few, if any, studies of brain iron levels in large cohorts of hemochromatosis patients. While liver damage, arthritis and diabetes are the most well documented clinical consequences of hemochromatosis, some clinical and epidemiological studies have suggested possible associations with neurologic problems, including extreme fatigue (Whitlock et al., 2006; Allen et al., 2008; McLaren et al., 2008) and severe headaches Stovner et al., 2002) .
Hemochromatosis is most commonly due to disease-causing polymorphisms in the HFE gene (Feder et al., 1996; Brissot et al., 1999; Olynyk et al., 1999) , however loss-of-function mutations in the transferrin receptor 2 (TFR2) gene have also been demonstrated as causative (Camaschella et al., 2000; De Gobbi et al., 2001; Roetto et al., 2001) . The TFR2 gene is transcribed in two main isoforms -the full-length form (α) and a shorter form (β) (Kawabata et al., 1999) . In the liver, the primary site of iron storage and regulation, both HFE and TFR2-α (but not TFR2-β (Roetto et al., 2010) ) are involved in regulating expression of the hormone peptide hepcidin, which in turn regulates dietary iron absorption (Nemeth et al., 2004) . Lossof-function mutations in either HFE or TFR2 lead to loss of hepcidin regulation and inappropriate iron absorption (Ajioka et al., 2002; Bridle et al., 2003; Nemeth et al., 2005; Drake et al., 2007) .
Evidence from in vitro studies of hepatocytes has been interpreted to suggest that HFE and TFR2 form part of a common feedback mechanism that regulates hepcidin expression (Gao et al., 2009) , however evidence from mice with combined deletion of Hfe and Tfr2 genes suggest that the HFE and TFR2 proteins are involved in parallel pathways (Wallace et al., 2009a; Wallace et al., 2009b; Delima et al., 2012) . It is not known whether HFE and TFR2 perform similar iron regulatory functions in other parts of the body, such as the brain, nor whether they are involved in common or parallel pathways in non-hepatic tissues.
We have previously investigated the effects of hemochromatosis on the brain by assessing the brain transcriptome in mouse models of dietary iron loading (Johnstone and Milward, 2010a) and HFE-related hemochromatosis (Hfe -/-mice) (Johnstone et al., 2012a; Johnstone et al., 2012b) . While these two models show comparable liver iron loading and no detectable brain iron loading, the brains of Hfe -/-mice show substantially more changes at the transcript level than dietary iron-supplemented mice, suggesting hereditary hemochromatosis has more widespread effects on the brain than dietary iron loading. It is unclear whether this is due to the chronic nature of the iron accumulation peripherally, or due to disruption of internal brain systems which rely on HFE function.
To investigate this further, we have assessed the brain transcriptome of Tfr2 mutant mice (Tfr2   mut   ) , another model of hereditary hemochromatosis that develops chronic iron loading, with the aim of delineating which brain effects are due to chronic systemic iron loading and which are due to gene-specific disruption within the brain. We also aimed to assess the replicability, in the Tfr2 mut model, of important findings from the Hfe -/-mouse study which could point to some of the underlying causes of neurologic sequelae reported for hemochromatosis patients.
Experimental Procedures

Animals
All animal work was conducted at the University of Western Australia and all protocols were approved by the institutional Animal Ethics Committee. The Tfr2 mutant mouse model (Tfr2 mut ) has been described previously (Fleming et al., 2002; Drake et al., 2007; Chua et al., 2010) . Mice are homozygous for the Tfr2 Y245X nonsense mutation, orthologous to the TFR2 Y250X mutation found in human patients (Camaschella et al., 2000) . Wildtype and Tfr2 mut mice were of the AKR strain, which has been shown to manifest a stronger iron loading phenotype than other mouse strains, with higher hepatic iron concentration and serum transferrin saturation (McLachlan et al., 2011) . All mice were male and were fed standard mouse chow from weaning. At 10 weeks of age, mice were sacrificed under anesthesia (50 mg/kg ketamine, 10 mg/kg xylazine; Troy Laboratories Pty Ltd, Smithfield, NSW, Australia) and perfused transcardially with isotonic saline. Brains were removed, snap-frozen in liquid nitrogen and stored at -80 0 C.
Iron measurements
Non-heme iron levels in brain and liver homogenates were assessed using the method of Kaldor (Kaldor, 1954) , as described previously (Johnstone and Milward, 2010a; Johnstone et al., 2012a Millipore, Billerica, MA, USA) followed by goat anti-mouse IgG-HRP secondary antibody
(1:2000; Santa Cruz Biotechnology). Images were obtained using a Versadoc imaging system and densitometry performed using the QuantityOne software package (Bio-Rad Laboratories, Hercules, CA, USA). Ferritin protein levels were quantified relative to levels of actin.
Microarray
Whole brains homogenates from biological replicates of wildtype mice (n=4) and Tfr2 mut mice (n=4) were subjected to RNA isolation using TRI Reagent (Ambion, Austin, TX, USA), according to the manufacturer's instructions. Following isolation, total RNA was purified and concentrated using the RNeasy MinElute Kit (QIAGEN, Hilden, Germany). Total RNA (500 ng) was prepared for microarray using the Illumina TotalPrep RNA Amplification Kit (Ambion).
The brain transcriptome was assessed using Illumina Sentrix MouseRef-8 (v1.1) BeadChip microarrays, which contain ~24,000 specific oligonucleotide probes. Arrays were scanned using the Illumina BeadArray Reader and BeadScan software. Data were analysed using BeadStudio v3 (Illumina, San Diego, CA, USA), with normalization by Cubic Spline and differential expression analysis using the Illumina Custom algorithm. This generated a list of probes with significant (p<0.05) differences in signal intensity between Tfr2 mut mice and wildtype controls. This probe list was then filtered by detection p-value in order to eliminate probes detecting non-specific signals. Probes assigned a detection p-value ≥0.01 in both control and Tfr2 mut groups were removed from further consideration. Probe annotations from the microarray manifest file were updated using the SOURCE database (http://smd.stanford.edu/cgi-bin/source/sourceSearch), using the listed NCBI transcript accession numbers as the search terms. Where the accession number was no longer listed in the database, annotations were updated by aligning the probe sequence against the mouse transcriptome using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Pathway classification and enrichment analysis
Pathway enrichment analyses were performed using the Database for Annotation, 
Results
Iron measures
Animals used in this study were aged 10 weeks, an age at which Tfr2 mut mice have been reported to manifest liver iron loading comparable to that in mild human hemochromatosis but no gross damage to the liver or other tissues (Drake et al., 2007) . This age is the same as that at which changes have been observed in our previous studies of other mouse models of iron loading (Johnstone and Milward, 2010a; Johnstone et al., 2012a) and facilitates assessment of early changes occurring in response to TFR2 dysfunction, uncomplicated by subsequent secondary effects.
As expected, liver non-heme iron levels were significantly higher (>3-fold) 
Expression of iron-related genes
The Tfr2 mut mice showed few expression changes for genes relating to iron metabolism or regulation. Transcripts for TFR2 were detectable in wildtype brain and significantly reduced in Tfr2 mut brain (2.2-fold decrease, p=0.007), presumably due to nonsense-mediated decay.
Other transcripts with key roles in iron metabolism or regulation, including hepcidin, showed either unaltered levels or were below microarray detection limits (data not shown). One notable exception was a significant increase in transcripts by microarray (1.3-fold increase, p=0.033) for ferritin light chain 1 (Ftl1), encoding an essential component of the iron storage protein ferritin, however this transcript level change was not validated by real-time RT-PCR ( Fig. 1) . Western immunoblotting of whole brain homogenate showed increased levels of total ferritin protein in Tfr2 mut mouse brain relative to wildtype controls (1.5-fold increase, p=0.01; Fig. 2 ), however we were unable to resolve light and heavy chain subunits.
Pathway enrichment analysis
To determine whether particular pathways were over-represented in the lists of differentiallyexpressed genes, we used the online tool DAVID to classify the list of significantly altered transcripts into KEGG pathways and assess pathway enrichment. This list was further divided into two sets comprising transcripts that were i) up-regulated or ii) down-regulated, and enrichment assessed within these subsets. While there were no significantly enriched pathways among the list of up-regulated transcripts, several pathways were identified as significantly enriched among the list of down-regulated transcripts ( Table 2 ). The most highly enriched pathway, which remained significant after adjustment for multiple hypothesis testing using the conservative Benjamini correction, related to long-term depression (LTD), with the related pathway of long-term potentiation (LTP) also identified as significantly enriched. These processes relate to a reduction or enhancement, respectively, in synaptic strength and efficacy and are key to the process of synaptic plasticity. The list of downregulated genes classified in these pathways is given in Table 3 . Notably, the long-term depression pathway was also identified as down-regulated in our previous study of Hfe -/-mouse brain (Johnstone et al., 2012b ).
There was also significant enrichment, among the list of down-regulated transcripts, of various pathways relating to cancer, most notably glioma ( Table 2) . Most of the genes identified in this pathway also form part of the LTD or LTP pathways ( As noted above, we have previously published studies of the brain transcriptome in mouse models of dietary iron loading (Johnstone and Milward, 2010a) and HFE hemochromatosis (Johnstone et al., 2012a; Johnstone et al., 2012b) , also aged 10 weeks. Comparison of differentially-expressed gene lists from the three different models of iron loading revealed 34 transcripts common to all lists (Fig. 3) . Strikingly, for these 34 transcripts (shown in (Fig. 1) , having been validated previously in the Hfe -/-mice (Johnstone et al., 2012a ). There were also decreased transcripts in both models for insulin-like growth factor 1 receptor (Igf1r), involved in LTD and other important brain functions (Bondy and Cheng, 2004) . Again this decrease was validated by real-time RT-PCR in both Tfr2 mut mice (Fig. 1) and Hfe -/-mice (Johnstone et al., 2012a) .
Furthermore, both models show reduced transcripts for the calcium channel gene Cacna1a (Table 5) , another component of the LTD pathway, and this was also validated by real-time RT-PCR ( Fig. 1) . In humans, the CACNA1A gene is causatively linked to familial hemiplegic migraine (Ducros et al., 1999; Hans et al., 1999; Pietrobon, 2002) and may provide an intriguing explanation for the increased prevalence of severe headaches reported for people with hemochromatosis or brain iron abnormalities Stovner et al., 2002; Boes et al., 2006; Gaul et al., 2007) . (Fig. 1) , consistent with the finding in Hfe -/-mice (Johnstone et al., 2012b) .
Key transcripts identified as altered in
Discussion
This study of the brain transcriptome in the Tfr2 mut mouse model of hereditary hemochromatosis, together with our previous studies in age-matched dietary ironsupplemented (Johnstone and Milward, 2010a) and Hfe The Tfr2 mut mouse model display a similar iron phenotype to the Hfe -/-and dietary ironsupplemented mice we have reported previously, with significantly increased liver iron levels relative to control mice but no change in brain iron levels. This was confirmed using two different methods (non-heme iron assay, ICP-AES). Interestingly, despite the lack of detectable brain iron changes, there were increased levels of ferritin protein. Ferritin is regulated post-transcriptionally by intracellular iron levels through the iron-responsive element/iron regulatory protein (IRE/IRP) system -an increase in ferritin protein in the absence of an increase in transcripts is generally indicative of an increase in intracellular 'free' iron (Hentze and Kuhn, 1996; Muckenthaler et al., 2008) . The findings may therefore indicate a redistribution of iron within the Tfr2 mut mouse brain to favour more iron moving into a stored form, either through redistribution between extracellular and intracellular compartments or redistribution between subcellular compartments. While there were no detectable alterations in transcripts for iron transporters such as ferroportin or divalent metal transporter 1 that might mediate these kinds of redistribution, translation of these transcripts is also regulated by the IRE/IRP system (Muckenthaler et al., 2008) , so changes may only be evident at the protein level.
A number of key genes identified in our previously published transcriptomic studies of the Hfe -/-mouse model of hemochromatosis (Johnstone et al., 2012a; Johnstone et al., 2012b) also showed expression changes in the Tfr2 mut mouse model, validating our previous findings and providing support for the assertion that disruption of iron homeostasis can lead to important changes in the brain. These include effects on genes involved in long-term depression, a molecular pathway that was significantly enriched among down-regulated transcripts in the two models.
Long-term depression, characterized by a long-lasting decrease in synaptic strength, is a key process in neural plasticity and therefore in learning and memory. Findings from animal models suggest that brain region-specific disruption of LTD results in a diminished capacity for specific types of learning and memory, as reviewed elsewhere (Collingridge et al., 2010) .
As described in more detail by Collingridge and colleagues, LTD is proposed to have roles in a range of cognitive functions, including hippocampus-dependent learning and memory (Brigman et al., 2010) , fear conditioning in the amygdala (Migues et al., 2010) , recognition memory in the perirhinal cortex (Griffiths et al., 2008) and cerebellar learning (Massey and Bashir, 2007) .
It is therefore conceivable that the reduced expression of key genes relating to LTD observed in our mouse models of hereditary hemochromatosis will have a detrimental impact on various facets of learning and memory. Behavioural studies of these models, together with electrophysiological studies of brain slices to determine net effects on LTD/LTP, will help clarify this issue. In addition, it would be valuable to thoroughly assess learning and memory in large cohorts of patients with clinical hemochromatosis (i.e. not just individuals with predisposing mutations) and to further investigate suggestions of detrimental effects of high hippocampal iron on verbal memory and high basal ganglia iron on working memory (Bartzokis et al., 2011) .
As far as we are aware, there have been no studies of the effects of iron loading on glioma susceptibility, however high expression of TFR2 in glioblastoma biopsies is positively correlated with patient survival (Calzolari et al., 2007; Calzolari et al., 2010) . It was therefore interesting to observe reduced expression of various genes in the 'glioma' pathway in Tfr2 mut brain, including the important and closely related oncogenes Kras and Raf1. Although activating mutations in KRAS and RAF1 are required for oncogenicity or in Noonan Syndrome (a common developmental disorder), deletion of either gene in mice causes embryonic lethality (Johnson et al., 1997; Huser et al., 2001; Mikula et al., 2001) , indicating that both genes are essential for normal function. The consequences of reduced expression of these genes in the brain is unclear but suggest potentially important effects on the RAS-MAPK signal transduction pathway, which could have far-reaching effects on the intracellular cascades that control the cell cycle.
While there were similarities between the brain transcriptome profiles of Hfe -/-and Tfr2 mut mice, there were also a number of differences, with Tfr2 mut mice showing far fewer changes relative to wildtype controls than Hfe -/-mice. The reasons for this are unclear but may relate to differences in the expression patterns of HFE and TFR2 in the brain. Although there are few relevant studies to date, HFE transcripts appear to be widely expressed across different brain regions, albeit at low levels (Hanninen et al., 2009 ). In addition, immunohistochemical studies have provided preliminary evidence that HFE protein is expressed by brain capillary endothelial cells, choroid plexus and ependymal cells (Connor et al., 2001) , in addition to scattered cells, possibly astrocytes, throughout the cortex and cerebellum (Bastin et al., 1998) .
In contrast, while there has been even less investigation of TFR2 in the brain, some evidence suggests that TFR2 expression is confined to the cerebellum in humans (Hanninen et al., 2009 ) and that transcripts for TFR2-α are below RT-PCR assay detection limits when averaged across the whole mouse brain (Kawabata et al., 1999) . The roles of TFR2-α in the brain may therefore be restricted to particular regions, notably the cerebellum, while disruption of HFE may have the potential to affect systems across a larger number of brain regions.
It should be noted, however, that while transcripts for TFR2-α are present at low levels, transcripts for TFR2-β are strongly expressed in mouse brain (Kawabata et al., 1999) . This isoform of TFR2 is not involved in hepcidin regulation but is proposed to be involved in transcriptional regulation of the cellular iron export protein ferroportin in the spleen (Roetto et al., 2010) and, while its functions in the brain are not known, disruption of the Tfr2 gene and consequently the TFR2-β isoform could potentially have far-reaching effects within the brain.
While this study has illuminated several important effects of iron loading disorders on the brain, some specific limitations warrant discussion. First, both the evaluations of iron levels and the transcriptomic studies focused on whole brain rather than specific regions. Due to differences in the distribution and functions of iron across different brain regions and cell types, the downstream effects of perturbed iron homeostasis are likely to vary between different brain compartments. It will be informative in future studies to investigate transcriptomic profiles of particular brain regions to determine if changes are global or restricted to certain regions, specifically regions with high concentrations of iron such as the basal ganglia (Hallgren and Sourander, 1958; Hill and Switzer, 1984; Bartzokis et al., 1997) , as well as validating array results at the protein level using immunohistochemistry. In addition, it will also be valuable to further characterize the different forms of TFR2 and investigate their expression and functions in different brain regions.
Second, Tfr2 mut mice showed no net brain iron loading relative to wildtype mice. It is therefore important to note that this is not a model for studying the effects of gross brain iron accumulation -rather it provides a model for investigating the effects of both systemic iron loading in general and TFR2-related iron loading in particular on the brain transcriptome. The observed effects may be due to disruption of internal brain systems that normally rely on TFR2 or due to peripheral effects of iron loading being transduced to the brain. We plan in future studies to investigate models of more severe hemochromatosis, which we expect to have detectable brain iron accumulation.
In summary, the transcriptome perturbations observed in the brains of Tfr2 mut mice add to the growing body of evidence that disorders of systemic iron loading have important effects on the brain. The findings highlight changes to some specific molecular systems, such as longterm depression, that might partly explain sporadic reports of neurologic sequelae in some hemochromatosis patients. 
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